当前，云南省结核病临床诊疗工作面临耐药结核、结核与呼吸系统疾病共病等挑战。临床专业分会的成 立，将凝聚全省临床、影像、病理、药学等领域的专家智慧，构建"精准诊断、规范治疗、全程管理"的 防控体系，为患者提供更优质的医疗服务。 云南省防痨协会理事长查舜表示，临床专业分会的成立是回应群众健康期盼的重要举措。此举标志着全 省结核病防治工作从"单兵作战"迈向协同创新，从经验传承转向智慧融合。 本报讯 记者张晓莉报道 近日，云南省防痨协会临床专业分会在昆明揭牌成立。来自全省28家医疗机构 的100余名防痨领域人员参会，昆明市第三人民医院胸外科主任和进堂成为首任主任委员。 ...

（来源：天津日报） 转自：天津日报 精准推进早期发现，拓宽筛查覆盖范围。强化高风险人群精准筛查，对活动性肺结核患者开展流行病学 调查，对其密切接触者开展结核潜伏感染检测和结核病检查；加强学校新生、教职工体检，在重点学 段、高疫情地区来津生源中开展结核病检查，探索将结核病检查纳入精神病医院和救助保护机构新入院 （入职）检查和定期检查的内容；加强社区、企业等人口流动频繁且人员密集场所的结核病防控，积极 推广使用便捷有效的筛查技术，推进"无结核社区"试点深化。 提升诊疗管理质量，强化全流程管理。强化市区两级结核病疫情监测医院的病例早发现和报告职能，对 就诊的具有肺结核可疑症状者和发病高风险人群开展结核潜伏感染检测、胸部影像学和病原学等检查； 为结核病患者提供覆盖筛查、诊治和随访的全程管理服务；结合国家基本公共卫生服务项目和家庭医生 签约服务，各基层医疗卫生机构利用智能化服药管理系统，对辖区肺结核患者进行规范的督导管理。 加强患者关怀救助，减轻疾病负担。按规定将符合条件的药品纳入基本医疗保险支付范围；适时调整基 本医疗保险门诊、住院特殊病种支付限额，对治疗、预防结核病的药物不纳入药占比范畴；为符合条件 的结核病患者提 ...

Core Insights - The World Health Organization's annual report indicates that while there has been some progress in tuberculosis prevention and control, tuberculosis remains one of the deadliest infectious diseases globally, with over 1.2 million deaths expected in 2024 [1] Funding and Resource Challenges - The report highlights a persistent challenge in tuberculosis prevention and control due to a lack of funding and medical resources [1]

Core Insights - Tuberculosis remains one of the deadliest infectious diseases globally, causing over 1.2 million deaths and approximately 10.7 million infections last year [1] - From 2023 to 2024, the global incidence of tuberculosis decreased by nearly 2%, and the number of tuberculosis-related deaths declined by 3% [1] - Despite significant progress in diagnosis, treatment, and innovation in tuberculosis care, challenges such as funding shortages and equitable access to healthcare services persist, potentially jeopardizing the hard-won gains in combating tuberculosis [1]

Core Viewpoint - A new high-sensitivity and high-specificity tuberculosis (TB) testing reagent has been developed by Zhang Wenhong's team, which can quickly and easily detect TB nucleic acids in tongue swabs, with a cost of less than $1 [3][5]. Group 1: Tuberculosis Overview - Tuberculosis remains a significant global public health issue, with over 10 million new cases and more than 1.5 million deaths annually, making it the leading infectious disease killer [3][5]. - The World Health Organization (WHO) reported a rise in TB diagnosis rates in 2023, with 8.2 million new confirmed cases, the highest since monitoring began in 1995, surpassing the 7.5 million cases in 2022 [3][5]. Group 2: Current Situation in China - China has transitioned to a medium TB incidence rate, but in 2022, there were an estimated 748,000 TB patients, accounting for over 7% of global cases, ranking third in the world [5][6]. - In Shanghai, the TB incidence rate is 20 per 100,000 people, indicating the need for continued efforts to eliminate the disease [5][6]. Group 3: Treatment and Prevention Strategies - TB is curable with standardized drug regimens, and prevention can be achieved through screening and vaccination [5][6]. - Zhang Wenhong's team has researched short-course treatment regimens, reducing the treatment duration for drug-resistant TB from 1.5-2 years to 6-9 months, making it accessible for impoverished regions [6].

Core Insights - Tuberculosis (TB) remains a significant global public health issue, with over 10 million new cases and more than 1.5 million deaths annually, making it the leading infectious disease killer worldwide [1][2] Group 1: New Diagnostic Development - A high-sensitivity and high-specificity TB diagnostic reagent has been developed by a team led by Zhang Wenhong, which can quickly and easily detect TB nucleic acids from tongue swabs [1] - The cost of this new diagnostic reagent has been reduced to less than $1, enabling screening in high-incidence areas where 5 to 6 TB patients can be identified per 1,000 people screened [1] Group 2: Global TB Statistics - The World Health Organization (WHO) reported an increase in global TB diagnosis rates, with 8.2 million new confirmed cases in 2023, the highest since monitoring began in 1995, surpassing the 7.5 million cases in 2022 [1][2] - Approximately 1.08 million people are estimated to be infected with TB globally, with about 25% of the world's population carrying the TB bacteria [2] Group 3: China's TB Situation - China has transitioned to a medium TB incidence rate, with an estimated 748,000 cases in 2022, accounting for over 7% of global cases, ranking third in the world for TB burden [2] - In Shanghai, the TB incidence rate is 20 cases per 100,000 people, indicating ongoing challenges in eliminating the disease [2] Group 4: Treatment and Prevention Efforts - TB is curable with standardized drug regimens, and prevention can be achieved through screening and vaccination [2] - Zhang Wenhong's team has researched short-course treatment options, reducing the treatment duration for drug-resistant TB from 1.5-2 years to 6-9 months, making it more accessible in impoverished areas [3] - The team aims to enhance treatment adherence and reduce drug resistance by introducing better treatment plans and AI technology for rapid identification of active TB cases [3]

Core Insights - The Global Fund has made significant progress in combating AIDS, tuberculosis, and malaria since its establishment in 2002, saving 70 million lives [1][2] Group 1: AIDS Prevention - In 2024, 88% of people living with HIV in Global Fund-supported countries are aware of their status, with 79% receiving antiretroviral therapy and 74% achieving viral suppression, all reaching historical highs [1] - Since 2002, AIDS-related mortality has decreased by 82% and incidence has dropped by 73% in the supported regions [1] Group 2: Tuberculosis Prevention - In 2023, treatment coverage for all forms of tuberculosis in Global Fund-supported countries reached 75%, a significant increase from 45% in 2010 [1] - 44% of drug-resistant tuberculosis patients have begun treatment, with a treatment success rate of 88% [1] - The Global Fund has expanded the use of innovative tools such as AI-assisted detection and portable digital chest X-rays, improving timely diagnosis and treatment for more patients [1] Group 3: Malaria Prevention - In 2023, 61% of the population in Global Fund-supported countries had access to insecticide-treated nets, with 53% of at-risk populations using them [1] - Over 95% of symptomatic individuals received testing for malaria [1] Group 4: Challenges and Funding - The report warns of new challenges in disease control due to funding pressures and regional conflicts, highlighting the risk of reversing progress made over the past decades [2] - The Global Fund's Executive Director, Peter Sands, emphasizes the need for renewed commitment and increased investment from the international community to sustain health improvements [2] - In 2024, the Global Fund plans to invest $2.7 billion in over 100 countries to enhance disease monitoring and prevention efforts [2]